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Compromised neuroplasticity in 
cigarette smokers under nicotine 
withdrawal is restituted by the 
nicotinic α4β2-receptor partial 
agonist varenicline
G. Batsikadze1,2, W. Paulus1, A. Hasan5, J. Grundey1, M.-F. Kuo1,3 & M. A. Nitsche3,4
Nicotine modulates neuroplasticity and improves cognitive functions in animals and humans. In the 
brain of smoking individuals, calcium-dependent plasticity induced by non-invasive brain stimulation 
methods such as transcranial direct current stimulation (tDCS) and paired associative stimulation (PAS) 
is impaired by nicotine withdrawal, but partially re-established after nicotine re-administration. In order 
to investigate the underlying mechanism further, we tested the impact of the α4β2-nicotinic receptor 
partial agonist varenicline on focal and non-focal plasticity in smokers during nicotine withdrawal, 
induced by PAS and tDCS, respectively. We administered low (0.3 mg) and high (1.0 mg) single doses of 
varenicline or placebo medication before stimulation over the left motor cortex of 20 healthy smokers 
under nicotine withdrawal. Motor cortex excitability was monitored by single-pulse transcranial 
magnetic stimulation-induced motor evoked potential amplitudes for 36 hours after plasticity 
induction. Stimulation-induced plasticity was absent under placebo medication, whereas it was present 
in all conditions under high dose. Low dose restituted only tDCS-induced non-focal plasticity, producing 
no significant impact on focal plasticity. High dose varenicline also prolonged inhibitory plasticity. These 
results are comparable to the impact of nicotine on withdrawal-related impaired plasticity in smokers 
and suggest that α4β2 nicotinic receptors are relevantly involved in plasticity deficits and restitution in 
smokers.
Nicotine is the main component of tobacco responsible for the addictive properties of smoking. On the other 
hand, it positively impacts cognitive functions, such as working, episodic memory and attention1–3 in humans and 
animals. Clinical studies in patients with schizophrenia and Alzheimer’s disease have also revealed improvement 
of cognitive functions by nicotine4. However, other studies demonstrate negative or no effects of nicotine on cog-
nition2, 5, which might partially be explained by baseline performance differences between participant groups6. 
The physiological foundation for these cognitive effects is hypothesized to be nicotinic modulation of intracel-
lular Ca2+ concentration through α4β2 and α7 nicotinic acetylcholine receptors (nAChRs)7. These receptors are 
ligand-gated ion channels, involved in plasticity induction and cortical excitability modulation8, 9. In animal stud-
ies, with regard to plasticity, yet α4β2 and α7 nAChR activation yielded mixed results, producing enhancement of 
either LTP or LTD8, 10. Experiments in humans have shown that both, nicotine-induced non-selective activation 
of nAChRs, and targeted α4β2 and α7 receptor activation by respective agonists result in an increase of focal plas-
ticity, while abolishing the effects of more diffuse plasticity induction protocols in non-smokers11, 12. In contrast, 
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smokers under nicotine withdrawal display deficient facilitatory plasticity, probably caused by hypo-activation of 
desensitized nAChRs. In accordance, nicotine re-administration restitutes this impaired facilitatory plasticity13. 
The impact of nicotinic agents on glutamatergic plasticity is suggested to be mediated by nAChR-dependent neu-
ronal calcium influx in non-smoking subjects. In accordance, administration of nicotine, and hereby enhancing 
calcium influx, reestablished LTP-like plasticity abolished by dextromethorphan, which blocks NMDA receptors 
with calcium channel properties14.
Plasticity in the above-mentioned studies was induced by non-invasive brain stimulation protocols, such as 
transcranial direct current stimulation (tDCS) and paired associative stimulation (PAS). Both techniques induce 
long-lasting Ca2+- and NMDA receptor-dependent shifts in cortical excitability15, 16. tDCS non-selectively affects 
neuronal populations under the relatively large stimulation electrodes via subthreshold resting membrane poten-
tial modulation, inducing non-focal plasticity16, 17, whereas PAS induces relatively focal and synapse-specific neu-
roplastic changes, affecting mainly synapses between motor and somatosensory neurons15. For tDCS, LTP-like 
plasticity is induced by anodal, and LTD-like plasticity by cathodal stimulation of the target area16, while for PAS 
synchrony of activation of somatosensory-motor cortical connections determines plasticity direction, resembling 
spike-timing dependent plasticity15.
Apart from disturbed facilitatory plasticity, numerous studies in humans have reported that abstention 
from nicotine in smokers leads to deficits in working memory and attention18, 19, which are partially resti-
tuted by re-administration of nicotine or a α4β2 nAChR agonists20–22. However, in smoking humans the role 
of specific nAChRs in the re-establishment of impaired plasticity has not yet been explored. The fact that the 
above-mentioned α4β2 nAChRs have calcium channel properties7 suggests their key role in the restitutive effect 
of nicotine on withdrawal-related impaired plasticity. Moreover, in non-smoking individuals, acute nicotine and 
varenicline (partial agonist to the α4β2 and full agonist to α7 nAChRs) administration produces fairly similar 
effects on stimulation-induced plasticity12, 23. Here, we aimed at exploring the effect of the α4β2 activation on 
impaired plasticity in smokers during nicotine abstinence. For this reason, we selected varenicline, due to its 
4000–5000-fold greater affinity for the α4β2 compared to that for α7 nAChRs24. We expected that 0.3 mg and 1 mg 
dosages of varenicline should produce results similar to those of global nAChR activation and thus ameliorate 
nicotine withdrawal-related plasticity deficits in smokers.
Materials and Methods
Subjects. Twenty-six healthy smokers aged 24.5 ± 3.7 years (16 females/10 males) were recruited. All of 
them were students (BA, MSc and Ph.D.) of the University of Göttingen and naïve to the stimulation techniques. 
Six participants (4 females/2 males) from the initial group left the study after two or three experimental ses-
sions: one participant (from the PAS experiment) cancelled the participation due to side effects and five partici-
pants (four from the tDCS, one from the PAS experiment) left the study due to their busy lesson schedules; data 
from these sessions were excluded from the analysis. From the remaining group of twenty participants, four (1 
female/3 males) took part in both, the tDCS and PAS parts of the study, therefore a group of twelve subjects aged 
25.4 ± 3.8 years (7 females/5 males) completed the tDCS and a group of twelve subjects aged 24 ± 3.4 years (6 
females/6 males) completed the PAS experiment. No preliminary tests were conducted to check the responsive-
ness of the subjects to either tDCS or PAS. All subjects were right-handed according to the Edinburgh handedness 
inventory25. None of them took any medication, had a history of a neuropsychiatric or medical disease, present 
pregnancy, or metallic head implants. All subjects gave written informed consent and were compensated for par-
ticipation. All subjects were smokers with a cigarette consumption of minimum 10 cigarettes a day for at least 5 
years continuously and a Fagerström score of at least 1 point, indicating a light degree of nicotine dependence26. 
They were not allowed to smoke for 10 hours (3 to 4 half-lives of nicotine27) before and during the experimental 
sessions. The investigation was approved by the Ethics Committee of the University of Göttingen, and conforms 
to the principles laid down in the Declaration of Helsinki.
Transcranial Direct Current Stimulation. tDCS was administered by a battery-driven constant current 
stimulator (neuroConn GmbH, Ilmenau, Germany) through a pair of rubber electrodes (with the cable connector 
centered on the side of the rubber pad) covered with saline-soaked sponges (35 cm2, 5 × 7 cm). The motor cortex 
electrode was fixed over the area representing the right abductor digiti minimi muscle (ADM) and the return 
electrode above the contralateral supraorbital area. Subjects received 1 mA of either excitability-enhancing anodal 
tDCS for 13 minutes or excitability-diminishing cathodal tDCS for 9 minutes over the primary motor cortex, 
which induces motor cortex excitability alterations lasting for about 1 h after intervention28, 29.
Paired Associative Stimulation. The peripheral electric pulse over the right ulnar nerve at the level of the 
wrist at an intensity of 300% of the sensory perceptual threshold was delivered by a Digitimer D184 multipulse 
stimulator (Digitimer, Welwyn Garden City, United Kingdom) and was followed by a TMS pulse over the M1 
representation of the abductor digiti minimi muscle (ADM) conducted by a Magstim 200 stimulator with an 
intensity to elicit single pulse MEPs of ~1 mV peak-to-peak amplitudes. In total, 90 paired pulses were delivered 
at a frequency of 0.05 Hz at ISIs of 10 ms (inhibitory PAS or PAS10) or 25 ms (facilitatory PAS or PAS25). During 
PAS, the participants were instructed to silently count the number of pulses to guarantee sufficient attention to the 
procedure, which has been shown to be crucial to obtain the desired after-effects30, 31.
Pharmacological Interventions. Low (0.3 mg) or high (1.0 mg) dosages of varenicline or 0.5 mg placebo 
were administered in two-piece non-transparent gelatin capsules (size 2.18 mm length, 6.35 mm external diame-
ter) three hours before the start of the non-invasive brain stimulation protocol, allowing the verum drug to reach 
its maximum plasma level32. 1 mg varenicline is a usual single oral dosage administered in smokers twice per day 
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to support cessation of cigarette consumption32–35 and both 0.3 and 1 mg doses of varenicline had a modulatory 
effect on both tDCS- and PAS-induced plasticity in a previous study of our group12.
Monitoring of motor cortical excitability. In order to measure excitability changes, MEPs were recorded 
from the right ADM by single-pulse TMS over the corresponding left primary motor cortex, conducted by a 
Magstim 200 magnetic stimulator (Magstim, Whiteland, Dyfed, United Kingdom) with a figure-of-eight mag-
netic coil (diameter of one winding −70 mm; peak magnetic field −2.2T). The coil was held tangentially to the 
skull, with the handle pointing posterior and laterally at 45° from the midline. The hotspot was defined as the coil 
placement, where the TMS pulse resulted consistently in the largest MEPs of the right ADM. Surface MEPs were 
recorded with Ag-AgCl electrodes in a belly-tendon montage. The signals were amplified, band-pass filtered (2 Hz 
to 2 kHz, sampling rate, 5 kHz) and digitized with a micro 1401 AD converter (Cambridge Electronic Design, 
Cambridge, UK), controlled by Signal Software (Cambridge Electronic Design, v. 2.13), and stored into a labora-
tory computer for offline analysis.
Experimental procedures. The participants were seated in a comfortable chair with head and arm rests. In 
the beginning, the motor cortex hotspot was identified by TMS and then the stimulation intensity was adjusted to 
elicit single pulse MEPs with peak-to-peak amplitudes of on average 1 mV. Then twenty-five MEPs were recorded 
for the determination of first baseline. To keep the EMG electrodes and TMS coil position constant throughout 
the session, their exact positions were marked with a waterproof pen. After first baseline recording, varenicline 
or placebo medication was administered. Three hours after intake of medication, a second baseline was recorded 
to monitor for a possible impact of the drug alone on cortical excitability (baseline 2), and TMS intensity was 
adjusted, if necessary (baseline 3). After determination of the second or third baseline, one of the plasticity induc-
tion protocols was applied (cathodal tDCS, anodal tDCS, PAS10 or PAS25) and twenty-five MEPs were recorded 
at time points of 0, 5, 10, 15, 20, 25, 30, 60, 90 and 120 minutes after tDCS. Further TMS measurements were 
conducted in the evening of the stimulation day (SE), next morning, at ~9:00 AM (NM), next noon, at ~12:00 PM 
(NN) and next evening, at ~6:00 PM (NE) (Fig. 1). To avoid interferences, the interval between two consecutive 
experimental sessions for a single subject was minimum seven days. Subjects were blinded for both, stimulation 
and medication conditions; the experimenter was blinded only for the medication condition.
Analysis and statistics. The individual means of 25 MEP amplitudes were calculated at each time point for 
every subject. MEPs in which the muscle was not relaxed (i.e. observable EMG background activity present before 
the onset of the MEP) were excluded from the analysis.
Baselines. Individual baseline MEP amplitudes and maximum stimulator output (%MSO) percentage values 
for each session were analyzed with repeated measures analysis of variance (ANOVA) separately for tDCS and 
PAS experiments, using Baseline MEP or %MSO as dependent variable, respectively and session and medication 
(0.3 mg, 1.0 mg or placebo) as within-subject factors.
After-effects. post-stimulation mean MEP amplitudes were normalized to the respective mean baseline MEP 
amplitudes (quotient of post-stimulation vs pre-stimulation MEPs values: baseline 2, or, if TMS intensity was 
adjusted, baseline 3). Then the grand averages for each time point were calculated. A repeated measures ANOVA 
was performed on the above-mentioned data separately for tDCS and PAS experiments, using MEP amplitude as 
the dependent variable and medication, stimulation type and time course as within-subject factors.
Figure 1. Course of the study. Participants were not allowed to smoke 10 h before and during the experimental 
session. In the beginning of each session, 25 baseline single pulse MEPs were recorded at an intensity to elicit 
MEPs with peak-to-peak amplitudes of on average ~1 mV before administration of varenicline (0.3 or 1 mg) 
or placebo medication. Three hours later, a second baseline was recorded to explore the effect of medication 
on cortical excitability, and the stimulation intensity was adjusted, if necessary (third baseline). Next, tDCS 
(cathodal or anodal) or PAS (PAS10 or PAS25) was administered and blocks of 25 MEPs were recorded at time 
points of 0, 5, 10, 15, 20, 25, 30, 60, 90 and 120 minutes after plasticity induction. Further TMS measurements 
were conducted in the evening of the same day (SE), morning (at ~9:00 AM, NM), noon (at ~12:00 PM, NN) 
and evening (at ~6:00 PM, NE) of the second day.
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The Mauchley’s test was used to evaluate the sphericity assumption and degrees of freedom were corrected 
using the Greenhouse-Geisser method when necessary. In case of significant results of the ANOVA, exploratory 
post hoc comparisons were performed using Student’s t-tests (paired samples, two-tailed, p < 0.05, not corrected 
for multiple comparisons) between the MEP amplitudes before and after intervention within one experimental 
condition and between the single time points (medication vs placebo) within the same stimulation condition.
Bonferroni-corrected t-tests were not used in the exploratory secondary analysis, because the experiment was 
powered for the primary statistical test, i.e. the ANOVA. Furthermore, since post hoc t-tests were also applied 
in the majority of our foregoing related studies11–14, 23, we used identical tests in order to improve inter-study 
comparability.
To compare main effects of different dosages of varenicline on plasticity, averaged MEPs for the first 30 min-
utes after stimulation were calculated for each subject per experimental session and normalized to baseline 2 (or 
3, if TMS intensity was adjusted). These averaged MEP values for each dosage condition were tested via one-way 
ANOVA, exploratory post-hoc comparisons were conducted using Student’s t-tests (paired samples, two-tailed, 
p < 0.05, not corrected for multiple comparisons).
EMG measures were analyzed using custom python scripts based on the Stimfit library (version 0.14; available 
open source http://www.stimfit.org/doc/sphinx/)36. Statistical analysis was carried out with SPSS (version 23.0, 
IBM Corp.).
Results
All subjects tolerated the procedure well. Only one subject (from the PAS experiment) experienced dizziness, 
nausea, and vomiting under placebo medication and left the study.
On average, the interval between two consecutive experimental sessions was 11.8 ± 9.07 days.
Results of the Fagerström scores were 3.0 ± 1.8 (min 1; max 6) for the PAS and 3.5 ± 1.4 (min 1; max 6) for the 
tDCS group, indicating mild-to-moderate nicotine dependence37, with no significant differences as revealed by 
one-way-ANOVA (F(1, 22) = 0.559, p = 0.462) between stimulation groups.
Due to time constraints of participants, data were missing for the second day measurements (NM, NN and 
NE time points) for three subjects; in total, 8 time points in the tDCS and 3 in the PAS experiment (0.74% and 
0.27% of the data, respectively). The expectation maximization (EM) imputation method was used to replace the 
missing values38, 39.
Effect of varenicline on motor cortex excitability. Varenicline and placebo alone did not have any 
impact on cortical excitability at any dosage, as revealed by the repeated measures ANOVAs conducted on the 
baseline data (independently on MEP amplitudes and %MSO) separately for tDCS and PAS experiments (for 
details see Table 1).
Effect of varenicline on tDCS-induced plasticity. The RM-ANOVA revealed a significant 
MEDICATION × STIMULATION × TIME (F(28) = 1.877; p = 0.006) interaction (for details see Table 2).
Post-hoc Student’s t tests show that under placebo medication, tDCS induced no plasticity, as MEPs did not 
differ significantly from baseline values (the only exception being anodal tDCS at minute 60, where MEP size 
was significantly reduced compared to the baseline). Under both doses of varenicline, tDCS induced relevant 
excitability alterations. Cathodal tDCS induced a significant excitability diminution, lasting for 60 minutes after 
stimulation, whereas anodal tDCS induced an excitability enhancement, which was more prominent and stable 
under high dose varenicline (Fig. 2A,B).
For the effects of different dosages of varenicline on tDCS-induced plasticity, the grand average values calcu-
lated for the first 30 min after intervention were compared across groups by a one-way ANOVA and were signif-
icantly different (F(5, 66) = 11.951, p < 0.001). Both excitability-enhancing and -diminishing after-effects were 
present under low and high doses of varenicline compared to placebo (Student’s t test, paired samples, two-tailed, 
p < 0.01), under which no after-effects were observed (Fig. 3).
Effect of varenicline on PAS-induced plasticity. The RM-ANOVA revealed significant 
STIMULATION × TIME (F(14) = 2.897; p = 0.001) and MEDICATION × STIMULATION (F(2) = 6.718; 
p = 0.005) interactions (Table 2).
Post-hoc Student’s t - tests show that under placebo and low dose varenicline conditions, PAS failed to induce 
any excitability alterations. Here MEPs did not significantly differ from respective baseline values at any time 
point. Under high-dose varenicline, MEPs were significantly enhanced for 30 minutes after PAS25 and signifi-
cantly reduced for 120 minutes after PAS10 (Fig. 4A,B).
For the effects of different dosages of varenicline on PAS-induced plasticity, the one-way ANOVA conducted 
across groups on the grand average values calculated for the first 30 min after intervention was significant (F(5, 
66) = 4.817, p = 0.001).
Low dose varenicline did not restitute PAS-induced plasticity, MEP sizes after both PAS10 and PAS25 were 
similar to those after in the placebo condition, as revealed by the respective Student’s t-tests (paired samples, 
two-tailed, p < 0.05). Under high dose varenicline, both PAS25 and PAS10 induced excitability enhancement 
and diminution respectively, compared to the placebo condition (Student’s t - test, paired samples, two-tailed, 
p < 0.05) (Fig. 3).
Discussion
The results of this study demonstrate that nicotine withdrawal and nAChR activation under withdrawal has a 
notable effect on neuroplasticity in smokers. Under nicotine withdrawal, both tDCS and PAS-induced after effects 
were abolished, but reinstated by high dose varenicline. High dose varencline also resulted in prolongation of 
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tDCS-induced facilitatory and inhibitory after effects, whereas low dose medication succeeded in restitution of 
tDCS-induced after-effects, but was ineffective for PAS.
These results are partially similar to those acquired in a previous study, where a nicotine-withdrawal related 
abolishment of LTP-like facilitatory plasticity was reestablished by global nAChR activation13. Thus, we assume 
that the restitutive effect of nicotine on withdrawal-related impaired plasticity in smoking individuals is in large 
part caused by activation of α4β2 nAChRs. Moreover, similarly to another study of our group, conducted in 
non-smoking individuals, varenicline alone did not produce any effect on cortical excitability12.
Stimulation
TMS 
Parameter
Medication 
condition Baseline 1 Baseline 2 Baseline 3
Cathodal tDCS
MEP
0.3 mg 0.97 ± 0.13 1.01 ± 0.19 0.93 ± 0.13
1.0 mg 0.94 ± 0.11 0.81 ± 0.13 0.92 ± 0.06
Placebo 0.97 ± 0.13 1.06 ± 0.45 0.97 ± 0.12
%MSO
0.3 mg 57.17 ± 14.48 57.08 ± 14.57
1.0 mg 56.08 ± 14.15 56.67 ± 14.06
Placebo 56.50 ± 13.57 56.75 ± 14.07
Anodal tDCS
MEP
0.3 mg 0.95 ± 0.08 0.95 ± 0.13 1.00 ± 0.11
1.0 mg 0.99 ± 0.16 0.88 ± 0.15 0.93 ± 0.13
Placebo 1.00 ± 0.13 0.97 ± 0.15 0.99 ± 0.13
%MSO
0.3 mg 56.83 ± 13.11 57.25 ± 13.07
1.0 mg 57.08 ± 14.37 57.83 ± 14.83
Placebo 56.75 ± 14.00 57.17 ± 13.82
PAS10
MEP
0.3 mg 0.94 ± 0.10 1.05 ± 0.40 1.04 ± 0.15
1.0 mg 0.99 ± 0.10 0.86 ± 0.12 0.90 ± 0.08
Placebo 1.01 ± 0.14 0.93 ± 0.18 0.97 ± 0.10
%MSO
0.3 mg 57.08 ± 11.22 57.17 ± 11.63
1.0 mg 57.75 ± 11.95 58.25 ± 11.93
Placebo 56.67 ± 12.35 57.08 ± 12.38
PAS25
MEP
0.3 mg 0.92 ± 0.11 0.91 ± 0.21 0.95 ± 0.12
1.0 mg 0.97 ± 0.10 0.97 ± 0.19 0.98 ± 0.14
Placebo 1.01 ± 0.10 0.89 ± 0.15 0.94 ± 0.11
%MSO
0.3 mg 56.83 ± 12.34 57.00 ± 12.45
1.0 mg 57.17 ± 11.85 57.58 ± 11.95
Placebo 57.25 ± 11.42 57.58 ± 11.42
Table 1. MEP amplitudes and stimulation intensity before and after varenicline administration. Shown are the 
mean MEP amplitudes ± S.D. and stimulation intensity (percentage of maximum stimulator output, %MSO) 
means ± S.D. of baselines 1, 2 and 3. The intensity of TMS was adjusted to elicit MEPs with peak-to-peak 
amplitude of ~1 mV (baseline 1). A second baseline (baseline 2) was recorded three hours after varenicline or 
placebo intake to determine the impact of the drug on cortical excitability and adjusted if necessary (baseline 3). 
RM-ANOVAs revealed no significant differences between %MSO values and MEP amplitudes.
Experiment Factor Df F p
tDCS
Medication 2 0.531 0.596
Stimulation 1 11.862 0.005*
Time 14 0.769 0.701
Medication × stimulation 2 11.765 <0.001*
Medication × time 28 0.518 0.981
Stimulation × time 14 6.013 <0.001*
Medication × stimulation × time 28 1.877 0.006*
PAS
Medication 2 0.486 0.621
Stimulation 1 27.095 <0.001*
Time 14 0.907 0.553
Medication × stimulation 2 6.718 0.005*
Medication × time 28 0.868 0.661
Stimulation × time 14 2.897 0.001*
Medication × stimulation × time 28 1.136 0.294
Table 2. Results of the repeated measures ANOVA. *Significant results at p < 0.05.
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Non-invasive brain stimulation protocols induce NMDA receptor- and Ca2+-dependent LTP- and LTD-like 
plasticity40, 41. Modulation of membrane penetrability to calcium ions impacts upon the induction of LTP and 
LTD42 and thus should be able to alter these after-effects. Nicotinic receptors that influence intracellular Ca2+ 
Figure 2. Impact of varenicline on tDCS-induced neuroplasticity. Shown are baseline-normalized MEP 
amplitudes after plasticity induction by anodal (A) and cathodal (B) tDCS under 0.3 mg, 1.0 mg varenicline or 
placebo medication conditions up to the evening of the post-stimulation day. (A) In smokers under placebo 
medication, anodal tDCS induced no excitability enhancement, while 0.3 mg and 1.0 mg varenicline resulted 
in enhanced MEP amplitudes after anodal tDCS. (B) In the placebo condition, cathodal tDCS failed to induce 
excitability alterations. In contrast, both low and high doses of varenicline led to significant inhibitory after-
effects of tDCS. Error bars indicate S.E.M. Filled symbols indicate significant differences of post-stimulation 
MEP amplitudes from respective baseline values; Floating symbols indicate significant differences between the 
respective drug and placebo medication conditions at the same time points (Student’s t-test, two tailed, paired 
samples, p < 0.05).
Figure 3. In smokers under placebo medication, tDCS- and PAS-induced plasticity is abolished. Furthermore, 
PAS also induced no excitability alterations under 0.3 mg varenicline. High dose varenicline restituted 
both tDCS and PAS-induced after-effects, while 0.3 mg varenicline only restored tDCS-induced plasticity. 
Each column represents the mean of baseline-normalized MEP ± S.E.M. amplitudes until 30 minutes after 
stimulation; Asterisks indicate significant differences between drug and placebo conditions (Student’s t-test, two 
tailed, paired samples, p < 0.05).
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concentration are α4β2 and α7 nAChRs43. These receptors are relevant for LTP and LTD induction44, since they 
influence glutamatergic plasticity through intracellular calcium influx8, 9. Thus, administration of nicotine or 
varenicline leads to an elevated intracellular Ca2+ concentration via activation of respective subsets of nAChRs45, 
and affects stimulation-induced after - effects likely through this mechanism11, 12.
The lack of LTP-like plasticity in smokers can be explained by desensitization46, 47 and/or long-lasting inac-
tivation of nAChRs under withdrawal after chronic nicotine consumption, the latter being observed even up to 
5 hours after drug removal in rat brain tissue48, 49. Additionally, possibly due to the absence of the stimulatory 
effect of nicotine, a decrease of glutamate transmission is also observed during nicotine withdrawal50, 51. Failure of 
the facilitatory protocols to induce plasticity under nicotine withdrawal was also observed in a previous study of 
our group23, but here, both inhibitory PAS and cathodal tDCS still induced an excitability diminution. The reason 
for this discrepancy is unclear, as the groups are similar for age, gender distribution, Fagerstöm scores and with-
drawal durations. Possible explanations include inter-group differences of the effects of chronic nicotine exposure 
on other neuromodulatory systems such as dopamine and serotonin52, 53, as well as Brain-derived neurotrophic 
factor (BDNF) levels54, which are shown to have an impact on stimulation-induced plasticity55–57. Varenicline 
administration probably activated α4β2 nAChRs, which are assumed to be desensitized by chronic nicotine expo-
sure58, 59, thus facilitating intracellular calcium influx and therefore enabling either LTP or LTD-like after-effects 
after tDCS and PAS. Although varenicline is also a full agonist of α7 receptors, their impact on the restitutive 
effect of varenicline on impaired plasticity might be less relevant as (1) its affinity to α7 is 4000 to 5000 fold lower 
as compared to α4β224, (2) an α7 nAChR agonist failed to reduce nicotine withdrawal-associated cognitive deficits, 
as opposed to an α4β2 agonist, in another study60 and (3) in knockout mice nicotine withdrawal-related deficits in 
contextual fear conditioning involve β2, but not α7 subunit-containing nAChRs61.
The reason why low dosage varenicline succeeded in restitution of tDCS-induced plasticity, but failed in the 
PAS experiment can be explained by specific differences between these plasticity-inducing protocols. Since tDCS 
is assumed to induce plasticity by long-lasting tonic depolarization of relatively large neuronal populations under-
neath the stimulation electrodes, whereas PAS generates short depolarizations and affects only specific neuronal 
groups, tDCS might lead to stronger calcium increase, as compared to PAS, for a given individual. A somewhat 
similar effect was observed in an earlier study of our group, where in non-smoking participants both 0.3 and 
Figure 4. Impact of varenicline on PAS-induced neuroplasticity. Shown are baseline-normalized MEP 
amplitudes after plasticity induction by PAS25 (A) and PAS10 (B) under 0.3 mg, 1.0 mg varenicline or placebo 
medication conditions up to the evening of the post-stimulation day. Both, PAS25 and PAS10 induce no changes 
of MEP amplitudes in smokers under placebo or 0.3 mg varenicline conditions. (A) Cortical excitability was 
significantly enhanced for up to 30 minutes under high dose varenicline after PAS25 administration. (B) High 
dose varenicline restored inhibitory plasticity after PAS10. Error bars indicate S.E.M. Filled symbols indicate 
significant differences of post-stimulation MEP amplitudes from respective baseline values; floating symbols 
indicate significant differences between the respective drug and placebo medication conditions at the same time 
points (Student’s t-test, two tailed, paired samples, p < 0.05).
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1.0 mg varenicline abolished tDCS-induced after-effects, but only 1.0 mg had the same effect in the PAS condi-
tion12. These results are in agreement with the nicotine-induced calcium overflow in case of tDCS as demon-
strated by our recent study14, where reduction of calcium influx blocks the conversion of anodal tDCS-induced 
after effects from excitability enhancement to diminution under nicotine (which is not present for PAS-induced 
LTP-like plasticity) and thus is compatible with larger calcium influx via tDCS, as compared to PAS.
The abolishment of plasticity in smokers under nicotine abstinence and the restorative impact of varenicline 
goes in line with respective results of cognitive studies in humans and animals, where α4β2 receptor-targeting 
pharmacologic agents ameliorated working memory and attention impairments related to withdrawal after 
chronic nicotine administration22, 62.
The results of this study demonstrate that withdrawal from nicotine leads to deficiency in both LTD- and 
LTP-like plasticity, but is re-installed after administration of a nAChR agonist which activates receptors with 
calcium channel properties. These results suggest a key role of α4β2 nAChRs in pathophysiological alterations 
under nicotine withdrawal, but also restitution of normal physiological mechanisms. Since nicotine withdrawal 
also negatively affects such cognitive processes as attention, learning, working memory and response inhibition21, 
results of this study deliver a probable physiological foundation for these cognitive deficits, which however should 
be explored more directly in future studies.
With regard to the clinical domain, an involvement of the cholinergic system in schizophrenia has repeatedly 
been suggested63, 64. Additionally, the rate of smoking and daily cigarette consumption in schizophrenia patients 
is significantly higher than in the general population65. This led to the assumption that nicotine consumption is a 
kind of self-medication to improve schizophrenia-related cognitive deficits (“the self-medication hypothesis”)66. 
Recent studies have demonstrated that tDCS and excitatory PAS-induced plasticity are impaired in schizophre-
nia patients67–69. Interestingly, excitability diminishing after-effects of cathodal tDCS are still present in smoking 
patients as compared to non-smokers70. Additionally, non-smoking schizophrenia patients were significantly 
more responsive to repeated fronto-temporal tDCS sessions, resulting in a decrease in auditory hallucinations 
compared to smokers71, suggesting a complex interaction between impaired plasticity and the cholinergic system. 
In principal accordance with these studies, demonstrating that neuroplasticity is compromised in schizophrenia, 
our results can at least partially explain why nicotinic agents may have positive effects in this condition72, 73. 
However, this explanation is hypothetical and should be systematically addressed in future studies.
This study targeted the impact of a single dose varenicline on neuroplasticity during acute (~10 h) withdrawal 
from nicotine. Plasticity changes related to an extended nicotine withdrawal syndrome, related to smoking cessa-
tion, which lasts several weeks74, could be significantly different. Additionally, chronic administration of vareni-
cline might lead to discernible neuroplastic and/or cognitive changes as previously reported for nicotine75, as well 
as probable upregulation or desensitization of nicotinic receptors76, 77. Therefore, the effect of chronic adminis-
tration of varenicline on nicotine withdrawal-related plasticity alterations should be addressed in future studies.
It should also be noted that our study explored primarily the impact of α4β2 receptors on plasticity, however, 
α7 nAChRs have also shown to play an important role for respective processes44, 78. For more than a decade, there 
has been an increased interest to develop high affinity α7 nAChR-agonists capable to cross the blood-brain barrier 
and induce or enhance neuroplastic changes in the brain79, 80 for treatment of schizophrenia and Alzheimer’s dis-
ease81 as well as nicotine addiction82. Thus, future studies should be designed to specifically explore the involve-
ment of α7 receptors in nicotinic modulation of plasticity in humans.
The subjects recruited for our study were moderate smokers according to the Fagerström scale26. As was 
previously documented, an increase in the intensity of smoking in adults of all ages correlates with a decline in 
cognitive performance83–85, therefore plasticity changes in heavy smokers with stronger nicotine-dependence 
history may be qualitatively and quantitatively different. A systematic study involving different degrees of nicotine 
dependency could address this issue. Another limitation is the fact that neither blood nor breath CO tests were 
conducted to verify compliance of the subjects. Nevertheless, as the experimental sessions were mostly scheduled 
early in the morning and the participants were moderate smokers, we relied on their statements of compliance. 
Nicotine abstinence was also not verified after the 120th minute after intervention for the reason that the subjects 
were no longer present in the laboratory, thus it cannot be excluded that the late (SE-NE time points) neuroplastic 
effects of the stimulation were affected by nicotine consumption in some participants. Also tobacco craving (For 
example, Tobacco Craving Questionnaire86) and withdrawal (For example, Withdrawal Symptom Checklist87), 
which would have allowed to correlate physiological with behavioral data, was not assessed.
Between baseline 1 and 2 measurements the participants stayed in the local library, therefore it can be safely 
assumed that they were performing somewhat similar activities (e.g. reading, studying). However, in order to 
minimize the possible impact of the differences in these activities on the results of the experiment, an interim 
control would have been advantageous.
Obtaining tDCS and PAS-induced after-effect measures additionally during normal smoking behavior would 
have added potentially relevant data about plasticity in smokers under naturalistic conditions. This would have 
however added a substantial amount of experimental sessions, and we decided not to add these assessments, also 
in light of information we had obtained in a previous study about the impact of controlled nicotine administra-
tion in smokers13.
Furthermore, our experiment was limited to the motor cortex. Recently, an enhancement of cortical-evoked 
potentials after prefrontal PAS25 was demonstrated via TMS-EEG88. Since cognitive functions that are affected by 
nicotine abstinence, such as working memory, episodic memory and attention20 are related to the prefrontal cor-
tex89–92 and can also be modulated by non-invasive brain stimulation protocols93, 94 as well as nicotinic agents1–3, 
it would be relevant and feasible to focus the future exploration of nicotine withdrawal-related plasticity shifts 
directly on prefrontal cortex physiology.
Finally, we did not perform cognitive tests in order to directly connect neurophysiologic results to cognition. 
Although the results of this study could explain the restitutive effect of varenicline on nicotine withdrawal-related 
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cognitive deficits observed in several studies22, 62, 95, 96, this connection is still indirect and remains hypothetical. 
Thus, future studies should explore the direct relationship between changes in cortical excitability and cognition 
related to nicotine withdrawal and re-administration.
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